Axsome Therapeutics Inc

19X

Company Profile

  • Business description

    Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

  • Contact

    One World Trade Center
    29th Floor
    New YorkNY10007
    USA

    T: +1 212 332-3241

    E: [email protected]

    https://www.axsome.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    925

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,734.05363.01-0.74%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,986.05893.15-3.74%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5007,011.02164.81-2.30%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers